PDK1 / PDPK1 Cancer Research Results

PDK1 / PDPK1, Pyruvate dehydrogenase kinase 1: Click to Expand ⟱
Source:
Type:

PDPK1 - 3-Phosphoinositide-Dependent Protein Kinase 1

Abbreviation: PDPK1, PDK1

Type: Serine/threonine protein kinase / PI3K pathway signaling kinase / AGC kinase activator

Function: PDPK1 is a central signaling kinase downstream of phosphoinositide 3-kinase. It phosphorylates and activates multiple AGC-family kinases, including AKT, S6K, SGK, RSK, and selected PKC isoforms, thereby regulating proliferation, survival, metabolism, migration, and cellular growth.

Cancer: ↑ Frequently overexpressed, hyperactivated, or functionally dysregulated in cancer. Increased PDPK1 signaling enhances PI3K-AKT pathway output, proliferation, survival, migration, invasion, metastasis, metabolic adaptation, and resistance to anticancer therapies. Genetic or pharmacological suppression of PDPK1 can inhibit tumor growth and restore treatment sensitivity in experimental models.

Favorable Direction in Cancer: ↓ PDPK1 expression or kinase activity is generally favorable.
Pca, Prostate Cancer: Click to Expand ⟱
Prostate Cancer: Alterations in genes such as ERG, SPOP, MYC, androgen receptor (AR), and CHD1, drive PCa progression.
TP53 is the most commonly mutated gene in human cancer.
HH↑, GLI-1↑, SHH↑ P53↓
The loss of p53 and/or other tumor suppressor genes, reduced capacity for DNA repair, the dysfunction of telomerase activity, and changes in the pathways that govern the growth of cells also mediate the progression of Pca.
It has been well documented that Ca2+ influx and MDR1 upregulation are highly associated with GEM metabolism in human pancreatic carcinoma.
Increased Growth factor IGF-1/IGF-1R axis activation mediated by both PI3K/Akt or RAF/MEK/ERK system and AR expression remains important in the development and progression of prostate cancer.
It has been demonstrated that prostate cancer cells are relatively sensitive to heat stress.
Long non-coding RNA MALAT1 has been reported as an oncogenic target in multiple types of cancers, including PC.
Scientific Papers found: Click to Expand⟱
133- CUR,    Curcumin inhibits prostate cancer by targeting PGK1 in the FOXD3/miR-143 axis
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
miR-143↑, PDK1 / PDPK1↓, FOXD3↑, TumCP↓, TumCMig↓, *Inflam↓, *antiOx↑, *chemoPv↑, RadioS↑, ChemoSen↑,
6686- DAP,    Lactoferrin-encapsulated dichloroacetophenone (DAP) nanoparticles enhance drug delivery and anti-tumor efficacy in prostate cancer
- in-vivo, Pca, NA
PDK1 / PDPK1↓, TumCP↓, TumCMig↓, BioAv↓, BioAv↑, Apoptosis↑, Casp3↑, Casp7↑, Glycolysis↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis(tgid=4) ⓘ

Glycolysis↓, 1,   PDK1 / PDPK1↓, 2,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   Casp3↑, 1,   Casp7↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

FOXD3↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

miR-143↑, 1,  

Migration(tgid=13) ⓘ

TumCMig↓, 2,   TumCP↓, 2,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   ChemoSen↑, 1,   RadioS↑, 1,  
Total Targets: 13

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

Inflam↓, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoPv↑, 1,  
Total Targets: 3

Scientific Paper Hit Count for: PDK1 / PDPK1, Pyruvate dehydrogenase kinase 1
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:22  Cells:%  prod#:%  Target#:246  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page